A primary prevention study would also be worthwhile, he added—that is, giving nontoxigenic strain M3 to patients who are taking antibiotics “to see if we can colonize them and as a result protect them against C. difficile infection in the first place.”
“I think we are going to come up with new novel strains of bacteriotherapy or biotherapeutics that will really help us prevent some of the unintended consequences of antibiotic therapy,” Dr. Gerding said.
The study was sponsored by ViroPharma Incorporated, which is now part of the Shire group of companies. Dr. Gerding reports holding patents for the prevention of CDI licensed to ViroPharma/Shire and providing consultancy for ViroPharma/Shire.
Pages: 1 2 | Single Page
Loading ...
No Responses to “New Treatment for Recurrent C. difficile Shows Promise”